PMID- 22243699
OWN - NLM
STAT- MEDLINE
DCOM- 20120813
LR  - 20181201
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 17
IP  - 4
DP  - 2012 May
TI  - Experimental study of leflunomide on renal protective effect and on inflammatory 
      response of streptozotocin induced diabetic rats.
PG  - 380-9
LID - 10.1111/j.1440-1797.2012.01563.x [doi]
AB  - AIM: To further reveal the effects of leflunomide on renal protection and on 
      inflammatory response using streptozotocin (STZ) induced diabetic rats. METHODS: 
      Male Wistar rats were randomly divided into normal control group (NC), diabetic 
      group (DM) and leflunomide treatment group (LEF). LEF group rats were given 
      leflunomide (5 mg/kg) once daily. At the end of the 12th week, general 
      biochemical parameters in three groups were determined. The renal histopathology 
      was observed by light microscopy and electron microscopy. Further biochemical 
      analysis of the gene and protein expression of nuclear factor kappa B (NF-kappaB), 
      tumour necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) 
      and ED-1 positive cells in renal tissue were provided using real-time reverse 
      transcription-polymerase chain reaction and immunohistochemistry. RESULTS: 
      Compared with NC group rats, systolic blood pressure, blood glucose (BG), 
      glycohemoglobin (HbAlc), renal hypertrophy index, urine albumin excretion rate 
      (AER) and serum creatinine were increased in DM group rats (P < 0.05). Treatment 
      with leflunomide can improve these parameters except systolic blood pressure, BG 
      and HbAlc. Creatinine clearance rate (Ccr) in the DM group was significantly 
      lower than that of the NC group, and leflunomide can increase its level. Compared 
      with DM group rats, the pathological damages were significantly relieved in LEF 
      group rats. Compared with NC group rats, the gene and protein expressions of 
      NF-kappaB, TNF-alpha, MCP-1 and ED-1 positive cells in renal tissue of DM group rats were 
      highly upregulated (P < 0.01). Leflunomide suppressed their high expressions in 
      renal tissue of diabetic rats. CONCLUSIONS: Leflunomide can ameliorate the kidney 
      structure and function injury of diabetic rats through suppressing the expression 
      of NF-kappaB, TNF-alpha, MCP-1 and macrophage infiltration in renal tissue.
CI  - (c) 2012 The Authors. Nephrology (c) 2012 Asian Pacific Society of Nephrology.
FAU - Yu, Wei-min
AU  - Yu WM
AD  - Department of Internal Medicine of Renal Disease, Shanxi Dayi Hospital (Shanxi 
      Academy of Medical Sciences), China. snowfox168408@126.com
FAU - Wang, Huan
AU  - Wang H
FAU - Ren, Xiao-Jun
AU  - Ren XJ
FAU - Liu, Jun-Ping
AU  - Liu JP
FAU - Wang, Jian-Ying
AU  - Wang JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Isoxazoles)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - AYI8EX34EU (Creatinine)
RN  - G162GK9U4W (Leflunomide)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Biomarkers/blood
MH  - Chemokine CCL2/genetics/metabolism
MH  - Creatinine/blood
MH  - Cytoprotection
MH  - Diabetes Mellitus, Experimental/complications/*drug 
      therapy/genetics/immunology/metabolism
MH  - Diabetic Nephropathies/etiology/genetics/immunology/metabolism/*prevention & 
      control
MH  - Gene Expression Regulation
MH  - Immunohistochemistry
MH  - Immunosuppressive Agents/*pharmacology
MH  - Inflammation/etiology/immunology/metabolism/*prevention & control
MH  - Inflammation Mediators/metabolism
MH  - Isoxazoles/*pharmacology
MH  - Kidney/*drug effects/immunology/metabolism/pathology
MH  - Leflunomide
MH  - Male
MH  - NF-kappa B/genetics/metabolism
MH  - Nephrectomy
MH  - Rats
MH  - Rats, Wistar
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Necrosis Factor-alpha/genetics/metabolism
EDAT- 2012/01/17 06:00
MHDA- 2012/08/14 06:00
CRDT- 2012/01/17 06:00
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2012/08/14 06:00 [medline]
AID - 10.1111/j.1440-1797.2012.01563.x [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2012 May;17(4):380-9. doi: 
      10.1111/j.1440-1797.2012.01563.x.